GDF15 针对性治疗重症复发症的治疗目标
Jamie Thygerson1, Dallin Oyler1, Jackson Thomas1
1Department of Chemistry and Physics, Southern Utah University, Cedar City, UT 84720, USA.
Medicines (Basel, Switzerland)
|September 23, 2024
概括
怀孕期间的恶心和吐 (NVP) 影响了许多人,严重的妊娠高血压 (HG) 影响了生活质量. 针对GDF15蛋白的新疗法有望改善症状缓解和胎儿安全.
科学领域:
- 生殖医学 生殖医学
- 孕产妇和胎儿医学 孕产妇和胎儿医学
- 内分泌学 在内分泌学.
背景情况:
- 怀孕期间的恶心和吐 (NVP),特别是妊娠中高血压 (HG),影响高达70%的怀孕.
- 目前针对血清激素和多巴胺的治疗方法提供了不足的缓解,并导致副作用.
- 由胎盘产生的蛋白质GDF15越来越多地与NVP和HG症状有关.
研究的目的:
- 探索NVP和HG的新型治疗策略.
- 调查GDF15作为治疗目标来治疗与怀孕相关的恶心和吐.
- 解决有效和安全的治疗需要,并减少副作用.
主要方法:
- 审查最近关于GDF15在NVP和HG中的作用的研究.
- 探索创新的治疗方法,包括免疫疗法,小分子抗剂和透皮输送.
- 强调需要先进的动物模型进行临床前测试.
主要成果:
- GDF15是一种关键蛋白质,与NVP/HG有关,HG患者的水平发生变化.
- 针对GDF15的有希望的治疗策略正在出现,包括非IgG免疫疗法和小分子抗剂.
- 通过皮肤贴片等新的施用方法旨在提高疗效并减少不良事件.
结论:
- 准GDF15为开发NVP和HG更有效的治疗提供了一个有希望的途径.
- 进一步的研究和资金对于开发和测试先进疗法和动物模型至关重要.
- 这些治疗方法的成功开发可以显著改善患者的治疗结果,并降低医疗保健成本.
相关概念视频
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
181
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
181
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
236
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
236
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
153
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
153
01:17Drugs for Treatment of Diarrhea-Predominant IBS
152
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
152
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
274
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
274
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
222
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
222